PLSE - Company ID 0001625101
Pulse Biosciences, Inc. trades as PLSE and has a market capitalization of $1.92 B, making it the #2171 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $350.00K and net income of -$72.78M. This page tracks Pulse Biosciences, Inc. through 616 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Net profit margin compressed from -4489.4% to -20794.6% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade (amended) | 4/A | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-14 |
| SCHEDULE 13D/A | - | 2026-05-13 |
| Insider trade (amended) | 4/A | 2026-05-11 |
| Insider trade | 4 | 2026-05-11 |
| Insider trade | 4 | 2026-05-11 |
| Proxy statement | DEF 14A | 2026-05-11 |
| Major company event | 8-K | 2026-05-06 |
Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results | Pulse Biosciences Inc.
Management to discuss late-breaking data and the clinical program for its nPulse Cardiac Catheter System
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results | Pulse Biosciences Inc.
The largest companies sharing Pulse Biosciences, Inc.'s SEC industry classification (surgical & medical instruments & apparatus).
Pulse Biosciences, Inc. (PLSE) has a market capitalization of $1.92 B as of 2026-07-09, ranking #2171 among US-listed companies.
Pulse Biosciences, Inc. reported revenue of $350.00K for fiscal year 2025.
In its latest fiscal year Pulse Biosciences, Inc. reported a net loss of $72.78M.